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Abstract
Introduction: It has been suggested that changes in the production of adipose tissue hormones in obese postmenopausal women might 
affect their bone status. The aim of this study was to determine whether obese postmenopausal women exhibited any relationship be-
tween serum levels of LP, ADIPO, RES, VISF, APE and bone metabolism markers (OC and CTx), OPG, sRANKL, the OPG/sRANKL ratio 
as well as BMD. 
Material and methods: 80 postmenopausal women (60 obese and 20 healthy) underwent BMD measurement using dual-energy X-ray ab-
sorptiometry (DXA) at lumbar spine L2–L4. Serum levels of selected adipose tissue hormones, OC, CTx, OPG and its soluble ligand, sRANKL, 
were assessed by ELISA.
Results: Obese postmenopausal women demonstrated a significant increase in body mass, BMI and WHR associated with significant 
increases in LP and RES levels, a decrease in ADIPO concentration, suppression of OC, CTx, OPG and sRANKL and an increase in the 
OPG/sRANKL ratio and BMD. BMI correlated positively with BMD, LP, RES, OPG and the OPG/sRANKL ratio, whereas in the case of 
ADIPO, OC, CTx, sRANKL the relationship was negative. WHR was positively correlated with the OPG/sRANKL ratio, and negatively 
with ADIPO and APE. A positive correlation was found between BMD and LP, APE and the OPG/sRANKL ratio, while the correlation 
between BMD and ADIPO, CTx, sRANKL was negative. Significant positive correlations were also revealed between OC, CTx and ADIPO; 
OPG and ADIPO; sRANKL and ADIPO, RES; the OPG/sRANKL ratio and LP. OC correlated negatively with LP, RES, VISF, APE; CTx with 
LP, VISF, APE; OPG with LP; sRANKL with LP and APE; the OPG/sRANKL ratio with VISF. ADIPO was an independent predictor of OC, 
OPG and sRANKL, while LP turned out to be an independent predictor of CTx, OPG, sRANKL and the OPG/sRANKL ratio.
Conclusions: Obesity in postmenopausal women can lead to changes in BMD, circulating levels of bone markers, OPG, sRANKL and/or 
the OPG/sRANKL ratio; these changes are associated with alterations in the concentrations of adipose tissue hormones under investigation. 
The relationships between bone status indicators and adipose tissue hormones, especially LP and ADIPO, seem to suggest that changes 
in these hormones observed in obese postmenopausal women might have a protective effect on bone tissue, most probably via a shift in 
the OPG/sRANKL ratio towards a functional excess of OPG. (Endokrynol Pol 2014; 65 (6): 438–448)
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Streszczenie
Wstęp: Istnieją sugestie, że zmiany w produkcji hormonów tkanki tłuszczowej u otyłych kobiet po menopauzie mogą wpływać na stan 
kośćca. Celem pracy było wykazanie, czy u otyłych kobiet po menopauzie istnieje związek między stężeniami w surowicy LP, ADIPO, 
RES, VISF, APE a markerami metabolizmu kostnego (OC i CTx), OPG, sRANKL, wskaźnikiem OPG/sRANKL oraz BMD. 
Materiał i metody: U 80 kobiet po menopauzie (60 otyłych i 20 zdrowych) wykonano badanie BMD metodą dwuwiązkowej absorpcjome-
trii rentgenowskiej (DXA) obejmujące część lędźwiową kręgosłupa L2–L4 oraz oznaczono metodą ELISA stężenia wybranych hormonów 
tkanki tłuszczowej, OC, CTx, OPG i jej rozpuszczalnego ligandu sRANKL.
Wyniki: Istotnemu wzrostowi masy ciała oraz wskaźników BMI i WHR u otyłych kobiet po menopauzie towarzyszyło znamienne 
zwiększenie stężeń LP i RES, obniżenie stężenia ADIPO, supresja stężeń OC, CTx, OPG i sRANKL oraz wzrost wskaźnika OPG/sRANKL 
i BMD. Wykazano, istotną dodatnią korelację między BMI a BMD, LP, RES, OPG i wskaźnikiem OPG/sRANKL oraz ujemną z ADIPO, 
OC, CTx i sRANKL. Wartości wskaźnika WHR korelowały dodatnio ze wskaźnikiem OPG/sRANKL a ujemnie ze stężeniami ADIPO i 
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and suppressed apoptosis of mouse osteoblastic cell 
line MC3T3-E1 [20]. It also has a protective effect on 
cultured rat bone marrow mesenchymal stem cells [21]. 
Data from in vitro studies seems to suggest that adipose 
tissue hormones might regulate bone remodelling, not 
only directly, but also via the cytokines of the RANKL/ 
/RANK/OPG system [22, 23]. It has been documented 
that human adipocytes exhibit OPG and/or RANKL 
expression in vitro [24–26] and regulate OPG and 
RANKL expression by human osteoblasts [26]. Fat cells 
downregulate RANKL production by osteoblasts but, to 
a much larger extent, upregulate OPG secretion. Kühn 
et al. [26] found that the OPG/RANKL ratio in primary 
human pre-osteoblasts increased nine-fold (mRNA and 
protein) when stimulated with adipocyte-secreted fac-
tors. Moreover, osteoblasts which were prestimulated 
with adipocyte-secreted factors inhibited osteoclasts 
formation. 
The association between the adipose tissue hor-
mones and bone tissue has been confirmed by in vivo 
studies, which, however, do not always yield unam-
biguous results, not only in healthy persons but also 
in persons with eating disorders (including anorexia 
nervosa — AN — or obesity).
Investigations carried out in apparently healthy 
women and/or men generally revealed a negative cor-
relation between osteocalcin (OC), OPG and LP as well 
as between RANKL and ADIPO [27]. However, OC and/ 
/or bone alkaline phosphatase (B-ALP), collagen type 
I crosslinked aminoterminal telopeptide (NTx) and/or 
collagen type I crosslinked carboxyterminal telopeptide 
(CTx) were positively correlated with ADIPO both in 
healthy women [28, 29] and men [30, 31]. Additionally, 
OPG concentrations were higher in post- compared to 
pre-menopausal women [27]. The OPG/RANKL ratio 
was positively correlated with ADIPO and inversely as-
sociated with LP independent of the effect of age, BMI 
and menopausal status [27]. In studies involving pre- 
and postmenopausal healthy women, it was demon-
strated that serum LP levels were negatively correlated 
with bone mineral density (BMD), whereas ADIPO did 
not seem to exert any effect on bone mass [32]. In other 
studies, serum ADIPO negatively associated with BMD, 
Introduction
White adipose tissue, both subcutaneous and visceral, is 
a reservoir of a number of hormones which have both 
local (autocrine/paracrine) and systemic (endocrine) 
actions [1–3]. These hormones are important regulators 
of appetite and numerous metabolic, endocrine and 
immune functions of the organism [3–8]. Some of them 
are mainly produced in subcutaneous adipose tissue 
(leptin — LP, adiponectin — ADIPO) [2, 3, 9]; others 
(resistin — RES, visfatin — VISF) are predominantly 
secreted in the visceral adipose tissue [2, 3]. Apelin 
(APE) is expressed not only by adipocytes but has also 
been identified in vascular endothelium and the cells of 
several other tissues (lung, heart or brain) [10]. 
The most recent in vitro studies indicate that adipose 
tissue hormones might affect bone status. LP stimulates 
osteoblast differentiation of human bone marrow stro-
mal cells in vitro, enhances de novo collagen synthesis 
and bone matrix mineralisation [11–13]. It also inhibits 
adipogenesis [11], suppresses osteoclastogenesis in 
cultures of human peripheral blood mononuclear cells 
and spleen cells, and stimulates and inhibits the expres-
sion of osteoprotegerin (OPG) and receptor activator 
of nuclear factor-kB ligand (RANKL), respectively [11, 
14]. ADIPO stimulates proliferation, differentiation, and 
mineralisation of osteoblastic MC3T3-E1 cells [15, 16]. It 
also stimulates RANKL and inhibits OPG expression in 
human osteoblasts [16, 17]. RES is expressed in murine 
preosteoclasts and preosteoblasts (RAW 264.7, MC3T3-
E1), in primary human bone marrow stem cells and in 
mature osteoblasts [18]. Recombinant RES increases 
the number of differentiated osteoclasts and stimulates 
NF-kB promoter activity, which indicates a significant 
role of this adipocytokine in osteoclastogenesis. RES 
also enhances the proliferation of preosteoblastic cells, 
but only weakly interferes with genes commonly re-
garded as regulators of preosteoblast differentiation 
into osteoblasts [18]. VISF has been show to stimulate 
human osteoblasts proliferation and increase type I col-
lagen production, depending on the dose and time of 
administration [19]. VISF also enhances mineralisation 
of bone matrix osteoblasts. APE stimulated proliferation 
APE. Wykazano ponadto dodatnią korelację między BMD a stężeniami LP, APE i wskaźnikiem OPG/sRANKL oraz ujemną ze stężeniami 
ADIPO, CTx, sRANKL. Stwierdzono także dodatnią korelację między stężeniami: OC, CTx a ADIPO; OPG a ADIPO; sRANKL a ADIPO 
i RES; wskaźnikiem OPG/sRANKL a LP. Ujemną korelację wykazano natomiast między OC a LP, RES , VISF i APE; CTx a LP, VISF i APE; 
OPG a LP; sRANKL a LP i APE; wskaźnikiem OPG/sRANKL a VISF. Stwierdzono, że niezależnym predyktorem dla OC, OPG i sRANKL 
jest ADIPO, a dla CTx, OPG, sRANKL i wskaźnika OPG/sRANKL — LP. 
Wnioski: Otyłość u kobiet po menopauzie wywołuje zmiany w BMD, stężeniach markerów kostnych, OPG, sRANKL i/lub wskaźniku 
OPG/sRANKL, którym towarzyszą zmiany w stężeniach badanych hormonów tkanki tłuszczowej. Wykazane zależności między wykład-
nikami stanu kośćca a badanymi hormonami tkanki tłuszczowej, zwłaszcza LP i ADIPO, sugerują, że obserwowane u otyłych kobiet po 
menopauzie zmiany w stężeniach tych hormonów mogą wpływać ochronnie na tkankę kostną, najprawdopodobniej poprzez przesunięcie 
relacji OPG do sRANKL na korzyść funkcjonalnej przewagi OPG. (Endokrynol Pol 2014; 65 (6): 438–448)
Słowa kluczowe: menopauza; otyłość; hormony tkanki tłuszczowej; metabolizm kostny; OPG; sRANKL 
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and more significantly in postmenopausal women [28]. 
In contrast, other studies have indicated that ADIPO 
exerts an activity to increase bone mass by supporting 
osteoclastogenesis and activating osteoblastogenesis 
[33, 34]. When studying the relationships between 
LP, ADIPO, RES, VISF, APE and BMD, the majority of 
researchers concluded that ADIPO was the only inde-
pendent BMD predictor in postmenopausal women [29, 
35] and elderly men [31]. According to some authors, 
both LP and ADIPO turned out to be determinants 
of BMD in older women and men [36]. Oh et al. [37] 
found that from among researched adipocytokines 
(LP, ADIPO, RES), only serum RES level showed a sig-
nificant negative correlation with lumbar spine BMD 
in middle-aged men, although the variance was small. 
Our studies of females with AN demonstrated that 
serum LP, RES, VISF and APEL suppression and ADIPO 
elevation were associated with a decrease in bone mark-
ers levels, low values of the OPG/sRANKL ratio with 
a parallel increase in serum OPG and sRANKL [38]. 
Of the researched adipocytokines, VISF was shown to be an 
independent predictor of OC; APE and RES turned out to 
be independent predictors of CTx, and sRANKL; APE and 
ADIPO were independent predictors of OPG; and APE, 
LP and ADIPO were independent predictors of the OPG/ 
/sRANKL ratio. Abnormal concentrations of the above 
mentioned adipose tissue hormones observed in females 
with AN might affect the balance of the OPG/sRANKL 
system and potentially compromise the mechanism which 
compensates for bone remodelling disturbances [38].
The results in obese women evidenced significant 
increases in serum LP, RES and/or APE concentrations 
and a serum ADIPO decrease compared to age-matched 
non-obese women [39–47]. Other research has not 
observed significant differences between serum VISF 
concentrations in obese and non-obese individuals [48]. 
Still others demonstrated a decrease [49] or increase 
[50–52] of serum VISF levels in obese subjects compared 
to a control group. On the other hand, obese women 
exhibited a significant reduction in the circulating levels 
of bone markers, cytokines of the RANKL/RANK/OPG 
system (especially RANKL) as well as an increase in 
the OPG/RANKL ratio compared to age-matched lean 
women [44, 45, 53, 54]. In general, these changes were 
more pronounced in post- compared to premenopausal 
obese women [44, 45, 53, 54]. 
Only a few researchers have studied the effect of 
obesity on the relationship between adipose tissue 
hormones and bone status indicators in postmenopau-
sal women. Gannage-Yared et al. [55] did not find any 
correlation between LP, ADIPO and OPG levels when 
they compared obese and non-obese young individuals. 
Our previous studies on obese postmenopausal women 
revealed a significant positive correlation between LP 
and BMD, OPG as well as the OPG/sRANKL ratio, 
and a negative correlation between LP and ICTP, CTx, 
sRANKL [44, 45]. Saleem et al. [56], who investigated 
the relationships between LP, ADIPO concentrations 
and bone markers in postmenopausal women diag-
nosed with metabolic syndrome (MetS), only found 
a negative correlation between OC and LP, and a positive 
correlation between OC and ADIPO. Wu et al. [57] showed 
that an increase in trunk fat in older women and men 
with MetS correlated significantly with ADIPO reduction, 
while an increase in leg fat was correlated with increased 
circulating levels of this adipocytokine. Although in vitro 
studies tend to indicate relationships between RES, VISF 
or APE levels and bone tissue [18–21], no literature reports 
have been found regarding the effect of obesity on the re-
lationship between the above mentioned adipocytokines 
and bone status indicators in postmenopausal women. 
The aim of this study was to determine whether 
obese postmenopausal women exhibited any relation-
ship between serum levels of LP, ADIPO, RES, VISF, 
APE and bone metabolism markers (OC and CTx), 
OPG, sRANKL, the OPG/sRANKL ratio as well as BMD. 
Material and methods
The study comprised 60 obese postmenopausal women 
hospitalised at the Endocrinology Division of the 
Department of Pathophysiology and Endocrinology 
in Zabrze Medical University of Silesia in Katowice 
(Poland). After the exclusion of hormonal causes, the 
study participants were diagnosed with simple obesity. 
Insulin resistance, abnormal lipid profile or glucose 
tolerance test were excluded based on the results of 
the preliminary biochemical analyses. Other exclusion 
criteria included liver and kidney failure, coronary heart 
disease, arterial hypertension, diabetes, systemic con-
nective tissue disorders, neoplastic and autoimmune 
disease, thyroid hormone or steroid therapy (oestrogen/ 
/progestin therapy) and nonsteroidal anti-inflammatory 
agents. Women receiving antiresorptive or immunosup-
pressive therapy were also excluded. All study subjects 
had adult-onset obesity. The control group consisted of 
20 postmenopausal women with normal body weight.
All women underwent BMD measurement using 
dual-energy X-ray absorptiometry (DXA) at lumbar 
spine (L2–L4) on a Lunar DPX, USA. All measurements 
were performed by one operator. Densitometry values 
were presented as BMD [g/cm2], T-score (the number 
of standard deviations [SD] from young adults) and 
Z-score (the number of SD from age-matched subjects). 
The coefficient of variation (CV%) was 1.6%. 
Blood samples were collected between 8am and 
9am following a 12-hour fast. Centrifuged serum was 
frozen and stored at –75˚C until analysis. Determina-
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tions of the concentrations of adipose tissue hormones, 
OC, CTx, OPG and sRANKL were performed by ELISA 
method using the following kits: LP and ADIPO (Bio-
Vendor, LLC, USA), RES (Mediagnost, Germany), VISF, 
APE (Phoenix Pharmaceuticals Inc., Burlingame, CA, 
USA), OC (DSL Inc., USA), CTx (Nornic Bioscience 
Diagnostics A/S, Denmark), OPG and sRANKL (Bio-
medica, Austria). The respective sensitivity, intra- and 
inter-assay errors were: 0.5 ng/mL, 7.5 and 9.2% for LP; 
0.7 ng/mL, 7 and 8.2% for ADIPO; 0.3 ng/mL, 5 and 
6.8% for RES; 0.55 ng/mL, 5 and 14% for VISF; 0.09 ng/mL, 
5 and 14% for APE; 0.05 μmol/L, 5.8 and 7.3% for OC; 
0.08 nmol/L, 5.2 and 6.7% for CTx; 0.14 pmol/L, 7 and 
7.5% for OPG; 0.04 pmol/L, 5 and 7% for sRANKL. 
The database was prepared using Excel 2000 (Mi-
crosoft Corporation). Statistical analysis was carried 
out with Statistica 10 for Windows (StatSoft Inc., USA). 
The t-test was used to determine the significance of in-
tergroup differences (normal distribution of variables). 
In the case of non-normal distribution, the significance 
was tested using the Mann-Whitney U test. The rela-
tionships between body mass index (BMI), waist-to-hip 
circumference ratio (WHR), BMD, LP, ADIPO, RES, VISF, 
APE, OC, CTx, OPG, sRANKL and the OPG/sRANKL 
ratio were analysed by Spearman’s correlation. The 
level of significance was set at p ≤ 0.05. Stepwise regres-
sion analysis was used to determine whether and which 
of the adipose tissue hormones under investigation 
were independent predictors of bone markers, OPG, 
sRANKL and the OPG/sRANKL ratio (model entry was 
set at p = 0.05, and model exit at p = 0.05). 
The study was approved by the Regional Bioeth-
ics Committee of the Medical University of Silesia in 
Katowice (NN-013-24/I/03/04). 
Results
Our obese postmenopausal women showed a sig-
nificant increase in mean body mass, BMI and WHR 
values compared to the control group. A significant 
increase in mean serum LP and RES concentrations and 
a significant decrease in mean serum ADIPO were also 
found. These changes were associated with a significant 
decrease in mean serum OC and CTx levels, marked 
decreases in OPG and sRANKL, and a significant in-
crease in the OPG/sRANKL ratio compared to the con-
trol group. The mean concentrations of VISF and APE 
in obese postmenopausal women were only slightly 
increased compared to the control. Lumbar spine bone 
mineral density was significantly higher in obese post-
menopausal women compared to the control, whether 
expressed as BMD [g/cm2], T-score or Z-score (Table I). 
In obese postmenopausal women, BMI values corre-
lated significantly and positively with serum concentra-
tions of LP, RES and OPG, the OPG/sRANKL ratio and 
BMD (presented as [g/m2]). A significant and negative 
correlation was found between BMI values and serum 
concentrations of ADIPO, OC, CTx, sRANKL. Obese 
Table I. Mean values of age, height, body mass, body mass 
index (BMI), waist to hip circumference ratio (WHR), bone 
mineral density (BMDL2–L4, presented as [g/cm2] and T-score 
or Z-score), mean serum levels of selected adipose tissue 
hormones, osteocalcin (OC), collagen type I crosslinked 
carboxyterminal telopeptide (CTx), osteoprotegerin (OPG), 
soluble receptor activator of nuclear factor-kB ligand 
(sRANKL) and OPG/sRANKL ratio values in postmenopausal 
obese women and in the control group 
Tabela I. Średni wiek, wzrost, masa ciała, wskaźnik masy 
ciała (BMI), wskaźnik talia–biodra (WHR), gęstość mineralna 
kości (BMDL2–L4, wyrażoną w [g/cm
2] oraz jako T-score i 
Z-score), średnie stężenia wybranych hormonów tkanki 
tłuszczowej, osteokalcyny (OC), karboksyterminalnego 
usieciowanego telopeptydu łańcucha α1 kolagenu typu I 
(CTx), osteoprotegeryny (OPG), rozpuszczalnego ligandu 
receptora aktywatora czynnika jądrowego-kB (sRANKL) 
i wartości wskaźnika OPG/sRANKL u otyłych kobiet po 
menopauzie i w grupie kontrolnej
Variables Groups
Obese women
(n = 60)
Control group
(n = 20)
Age (years) 57.36 ± 3.69 57.25 ± 3.86
Height [m] 1.60 ± 0.08 1.57 ± 0.03
Body mass [kg] 88.68 ± 2.51* 74.98 ± 4.97
BMI [kg/m2] 35.89 ± 1.62* 24.36 ± 0.46
WHR 0.89 ± 0.07* 0.79 ± 0.03
BMDL2-L4 [g/cm2]
T-score
Z-score
1.172 ± 0.033*
–0.001 ± 0.21* 
0.38 ± 0.23*
1.117 ± 0.016 
–1.08 ± 0.17
–0.68 ± 0.18
Last menstrual period 
(years)
51.73 ± 2.14 50.00 ± 4.24
Time since physiological 
menopause (years)
6.45 ± 2.57 7.25 ± 2.22
Duration of obesity (years) 16.51 ± 4.83           –
Leptin (LP) [ng/mL] 70.36 ± 28.99* 11.05 ± 4.03
Adiponectin (ADIPO)  
[μg/mL]
8.80 ± 3.18* 10.62 ± 3.61
Resistin (RES) [ng/mL] 3.36 ± 1.05* 2.76 ± 1.01
Visfatin (VISF) [ng/mL] 53.62 ± 3.22 48.54 ± 3.32
Apelin (APE) [pg/mL] 141.72 ± 20.90 136.48 ± 19.32
OC [μmol/L] 5.21 ± 0.57* 6.14 ± 0.70
CTx [nmol/L] 3.02 ± 0.23* 5.74 ± 0.62
OPG [pmol/L] 4.47 ± 0.31* 5.45 ± 0.38
sRANKL [pmol/L] 0.87 ± 0.07* 1.06 ± 0.08
OPG/sRANKL ratio 24.74 ± 4.43* 12.46 ± 1.88
*p ≤ 0.05 vs. control group; T-score — the number of standard deviations [SD] 
from young adults; Z-score — the number of SD from age-matched subjects
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postmenopausal women exhibited a significant and 
positive correlation between WHR values and OPG/
sRANKL ratio. WHR values correlated also, significantly 
and negatively, with serum levels of ADIPO and APE. In 
obese postmenopausal women, a significant and positive 
correlation was found between BMD and serum levels of 
LP, APE as well as the OPG/sRANKL ratio. The correla-
tion between BMD and serum levels of ADIPO, CTx as 
well as sRANKL was significant and negative (Table II). 
In obese postmenopausal women, positive and 
significant correlations were revealed between serum 
concentrations of OC, CTx, OPG, sRANKL and ADIPO 
as well as between sRANKL and RES. The OPG/ 
/sRANKL ratio correlated significantly and positively 
with serum LP levels. However, negative and significant 
correlations in these women were revealed between 
serum concentrations of OC and LP, RES, VISF, APE; 
CTx and LP, VISF, APE; OPG and LP; sRANKL and LP, 
APE. The OPG/sRANKL ratio correlated significantly 
and negatively with VISF (Table II).
Stepwise regression analysis carried out in post-
menopausal obese women revealed that ADIPO was 
an independent predictor of OC (R2 = 0.342, p = 0.013). 
LP turned out to be an independent predictor of CTx 
(R2 = 0.890, p < 0.001). ADIPO and LP were inde-
pendent predictors of OPG (R2 = 0.422, p < 0.001) 
and sRANKL (R2 = 0.300, p = 0.024), while LP was 
an independent predictor of the OPG/sRANKL ratio 
(R2 = 0.426, p = 0.005) (Table III).
Discussion
Recent investigations seem to indicate that obesity is 
not a risk factor for osteoporosis [45, 58–63]. It has been 
demonstrated that postmenopausal women who are 
≥ 30% overweight exhibit higher BMD measured at 
lumbar spine (L2–L4), proximal femur and the radius 
compared to slim postmenopausal women [58, 60, 61, 
64]. Numerous authors have emphasised a significant 
positive correlation between BMI and BMD measured 
at lumbar spine and proximal epiphysis of the femur 
[58, 60, 61]. Compared to non-obese postmenopausal 
controls, our obese postmenopausal study participants 
(no insulin resistance, normal lipid profile and normal 
glycaemic response curve) showed an increase in L2–L4 
BMD, which was positively correlated with BMI; the 
results are consistent with those of other authors [45, 54, 
58–61]. BMD increase was associated with a decrease in 
bone turnover markers, OPG and sRANKL levels (the 
decrease was greater in the case of CTx than OC and 
in the case of sRANKL than OPG) and an increase in 
the OPG/sRANKL ratio. Our previous investigations 
revealed that mean circadian concentrations of CTx, 
sRANKL and the values of OPG/sRANKL ratio were 
Table II. Correlation between values of body mass index 
(BMI), waist to hip circumference ratio (WHR), bone mineral 
density (BMDL2–L4, presented as [g/cm2]) and selected adipose 
tissue hormones, osteocalcin (OC), collagen type I crosslinked 
carboxyterminal telopeptide (CTx), osteoprotegerin (OPG), 
soluble receptor activator of nuclear factor-kB ligand 
(sRANKL) and OPG/sRANKL ratio in postmenopausal obese 
women (n = 60)
Tabela II. Korelacja między wartościami wskaźnika 
masy ciała (BMI), wskaźnika talia–biodra (WHR), 
gęstością mineralną kości (BMDL2–L4, wyrażoną w [g/cm
2]), 
wybranymi hormonami tkanki tłuszczowej, osteokalcyną 
(OC), karboksyterminalnym usieciowanym telopeptydem 
łańcucha α1 kolagenu typu I (CTx), osteoprotegeryną (OPG), 
rozpuszczalnym ligandem receptora aktywatora czynnika 
jądrowego-kB (sRANKL) i wartościami wskaźnika OPG/
sRANKL u otyłych kobiet po menopauzie (n = 60)
Variables Values of correlation 
coefficients — R 
BMI [kg/m2] BMDL2-L4 [g/cm2] 0.259*
Leptin (LP) [ng/mL] 0.479*
Adiponectin (ADIPO) [μg/mL] –0.305*
Resistin (RES) [ng/mL] 0.454*
Visfatin (VISF) [ng/mL] NS
Apelin (APE) [pg/mL] NS
OC [μmol/L] –0.514*
CTx [nmol/L] –0.507*
OPG [pmol/L] 0.466*
sRANKL [pmol/L] –0.377*
OPG/sRANKL ratio 0.356*
WHR BMD [g/cm2] NS
Leptin (LP) [ng/mL] NS
Adiponectin (ADIPO) [μg/mL] –0.430*
Resistin (RES) [ng/mL] NS
Visfatin (VISF) [ng/mL] NS
Apelin (APE) [pg/mL] –0.428*
OC [μmol/L] NS
CTx [nmol/L] NS
OPG [pmol/L] NS
sRANKL [pmol/L] –0.348*
OPG/sRANKL ratio 0.448*
BMD [g/cm2] Leptin (LP) [ng/mL] 0.271*
Adiponectin (ADIPO) [μg/mL] –0.695*
Resistin (RES) [ng/mL] NS
Visfatin (VISF) [ng/mL] NS
Apelin (APE) [pg/mL] 0.254*
OC [μmol/L] NS
CTx [nmol/L] –0.625*
OPG [pmol/L] NS
sRANKL [pmol/L] –0.417*
OPG/sRANKL ratio 0.521*
*p ≤ 0.05 — statistically significant values of correlation coefficients
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significantly correlated with BMD in postmenopausal 
obese women [45, 54]. 
In our present study, the above relationships 
were confirmed. Obese postmenopausal women 
exhibited significant and negative correlations 
between BMD and CTx as well as sRANKL, while 
the correlation between BMD and the OPG/
sRANKL ratio was positive. Moreover, BMI cor-
related significantly and negatively with bone 
markers concentrations and sRANKL, while the cor-
relation between BMI and OPG as well as the OPG/ 
/sRANKL ratio was positive. Although no correlations 
were found between BMD and WHR, the latter cor-
related significantly and negatively with sRANKL and 
positively with the OPG/sRANKL ratio. The obtained 
results show that, as the degree of obesity increases, 
bone formation and resorption are both suppressed. 
The balance between these two processes is also dis-
turbed. The cytokines of the RANKL/RANK/OPG sys-
tem, and especially RANKL, might play an important 
role in the mechanism of these disturbances. Based 
on the results of the correlation analysis, it might be 
assumed that obesity-, adipose tissue distribution- and 
age-related changes in RANKL and the OPG/RANKL 
ratio might modify bone metabolism as evidenced by 
BMD changes seen in obese postmenopausal women. 
The observed changes in bone status indicators 
might be associated with impaired production of some 
osteotropic factors (mainly hormones) frequently seen 
in obese postmenopausal women [53, 54, 65–67]. It 
is assumed that factors which are essential for the 
maintenance of normal bone mineral density in obese 
individuals include oestrogens, androgens (and, in 
particular, adrenal androgens), melatonin, changes in 
calcium and vitamin D3 metabolism as well as changes 
in the relationships between hormones of the somato-
tropic axis [44, 45, 53, 54, 58, 62, 67]. Recent studies, and 
especially the results obtained in in vitro models, have 
indicated that some adipocyte-secreted factors, includ-
ing adipose tissue hormones, such as LP [11–14], ADIPO 
[15–17], RES [18], and maybe also VISF [19] and APE [20, 
21], might play a role in the mechanism which prevents 
obese women from bone mass loss after menopause. 
A direct and/or OPG- and/or RANKL-mediated action 
of the above mentioned adipocytokines might affect 
bone remodelling in obese postmenopausal women 
[17, 22, 23, 27, 68]. As particular adipocytokines may 
exert a similar or opposite effect on bone tissue cells and 
OPG and/or RANKL expression in human osteoablasts 
in vitro [11–22, 24, 26], it is quite difficult to predict the 
net effect of their actions on the balance of the OPG/ 
/RANKL system and/or bone remodelling and bone 
mass in vivo. The most recent in vitro studies [24, 26] 
seem to indicate a final stimulatory effect. An et al. [24] 
found OPG and RANKL expression in 3T3L1 murine 
adipocytes. They also observed that OPG mRNA ex-
pression increased with the differentiation of 3T3L1 
adipocytes, while RANKL expression was only slightly 
altered. OPG mRNA was expressed at higher levels in 
white adipose tissue than in brown adipose tissue and 
Table III. Correlationa between selected adipose tissue hormones, osteocalcin (OC), collagen type I crosslinked carboxyterminal 
telopeptide (CTx), osteoprotegerin (OPG), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and OPG/sRANKL 
ratio in obese women (n = 60) 
Tabela III. Korelacjaa między wybranymi hormonami tkanki tłuszczowej, osteokalcyną (OC), karboksyterminalnym 
usieciowanym telopeptydem łańcucha α 1 kolagenu typu I (CTx), osteoprotegeryną (OPG), rozpuszczalnym ligandem receptora 
aktywatora czynnika jądrowego-kB (sRANKL) i wartościami wskaźnika OPG/sRANKL u otyłych kobiet po menopauzie (n = 60)
Variables Bone markers Cytokines of RANKL/RANK/OPG system OPG/sRANKL ratio
OC
[μmol/L]
CTx
[nmol/L]
OPG [pmol/L] sRANKL [pmol/L]
Leptin (LP) [ng/mL] –0.738* –0.762* –0.257* –0.293* 0.667*
Adiponectin (ADIPO) [μg/mL] 0.928* 0.548* 0.280* 0.289* NS
Resistin (RES) [ng/mL] –0.333* NS NS 0.325* NS
Visfatin (VISF) [ng/mL] –0.738* –0,690* NS NS –0.381*
Apelin (APE) [pg/mL] –0.690* –0.833* NS –0.301* NS
Stepwise regression modelb
R2
p
ADIPO
0.342
0.013
LP
0.890
< 0.001
ADIPO
LP
0.422
< 0.001
ADIPO
LP
0.300
0.024
LP
0.426
0.005
NS — non significant values of correlation coefficients (p > 0.05); *p ≤ 0.05 — statistically significant values of correlation coefficients; adisplayed value represents the 
model variance explained by these parameters; bparameters entering the stepwise regression model
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was more abundant in the subcutaneous portion [24]. 
Kühn et al. [26] reported that adipocytes regulated 
RANKL and OPG expression in human osteoblasts. 
While RANKL expression was only slightly affected, the 
expression of OPG, a cytokine which blocks RANKL/ 
/RANK interaction in osteoclasts, was significantly 
altered. Osteoclasts formation from precursor cells 
significantly decreases during osteoblast preincubation 
with adipocyte-secreted factors. Hence the assumption 
that adipocytes not only stimulate preosteoblast prolif-
eration, but also affect osteoblast/osteoclast interaction, 
thus reducing the number of osteoclasts which play an 
important role in the resorption process. These in vitro 
findings could account for higher bone mass in obese 
individuals, especially women, and attribute this effect 
to some adipocyte-secreted factors, including adipose 
tissue hormones, on bone formation [26]. 
The majority of literature reports focus on the effect 
of menopause on the relationships between selected 
adipose tissue hormones (especially LP and/or ADIPO) 
and various bone status indicators in non-obese women 
with or without osteoporosis. Only a few researchers 
have investigated the influence of obesity and meno-
pause on the above mentioned relationships. 
Numerous researchers have emphasised a beneficial 
effect of LP on bone tissue in normal weight pre- and 
postmenopausal women [45, 59, 69–71]. The effect 
depends on BMI and body fat percentage. A majority 
of research reports indicate that lean women exhibit 
a BMI- and body fat percentage-dependent positive 
correlation between LP and BMD, and a negative cor-
relation between LP and bone markers, and especially 
bone resorption markers [59, 69–71]. Nevertheless, some 
authors have only observed a slight positive correlation 
between LP and BMD [72–75] and a significant negative 
correlation between LP and bone markers [73–75] in 
both pre- and postmenopausal women. Other inves-
tigators concluded that LP was associated with BMD 
but only in postmenopausal women [76, 77]; still others 
found a significant positive correlation between LP and 
BMD in both pre- and postmenopausal women [69]. 
Tenta et al. [27] demonstrated that LP levels were nega-
tively and significantly correlated with OC, OPG and 
the OPG/RANKL ratio among healthy women. They 
believe that the negative correlation between LP and 
the OPG/RANKL ratio might represent a component 
of a mechanism protecting these women against post-
menopausal bone loss. Blain et al. [70] concluded that 
LP was an independent BMD predictor of whole body 
and femoral neck BMD in postmenopausal women. 
Women suffering from postmenopausal osteoporosis 
exhibited weaker correlations between BMD, bone 
markers and LP compared to their healthy counterparts 
[78, 79]. Tenta et al.’s [27] investigations of healthy non-
obese women demonstrated that ADIPO levels were 
positively and significantly correlated with the OPG/ 
/RANKL ratio independent of the effect of age, body 
mass index and menopausal status. Several investiga-
tions carried out in apparently healthy women have 
indicated a negative and significant correlation between 
BMD and ADIPO concentrations [28, 31, 39, 80, 81]. On 
the contrary, other studies indicated that ADIPO exerts 
an activity to increase bone mass by supporting osteo-
clastogenesis and activating osteoblastogenesis [33, 34]. 
Zhang et al. [29] and Wu et al. [35] have shown that 
from among researched adipocytokines (LP, ADIPO, 
RES, VISF and APE), only ADIPO, but not fat mass, 
LP, RES, VISF or APE, was an independent predictor 
of BMD in postmenopausal women. Zhang et al. [29] 
also suggested that ADIPO may exert a negative effect 
on bone mass by promoting excessive bone resorption 
associated with bone loss in post-menopausal women. 
Some other investigators did not reveal a significant 
association between circulating ADIPO levels and 
BMD in apparently healthy women of child bearing 
age [32]. Sodi et al. [82] indicated that there is no sig-
nificant difference in the circulating concentration of 
fasting early morning total- or high molecular weight 
(HMW)-ADIPO in postmenopausal women with or 
without osteoporosis. However, the negative correlation 
between HMW/total-ADIPO ratio and OPG showed in 
these women indicate that ADIPO could influence bone 
metabolism by altering osteoblast production of OPG, 
thereby affecting osteoclasts mediated bone resorp-
tion [82]. Other researchers observed an OPG increase 
in postmenopausal women with osteoporosis and LP, 
ADIPO as well as RANKL upregulation in postmeno-
pausal women without osteoporosis [83]. 
As mentioned above, only a few researchers have 
studied the effect of obesity and menopause on the 
relationship between selected adipose tissue hormones 
and bone status indicators in women. Several studies 
have only assessed the association between obesity and 
the levels of some selected adipose tissue hormones in 
women of different ages. In general, the obtained results 
evidenced significant increases in LP and/or RES levels 
and serum ADIPO decrease in obese women. These 
changes were typically associated with obesity markers 
including BMI, WHR and/or body fat mass [39–46] indi-
cating a relationship between these adipocytokines and 
obesity. We obtained similar results in our studies on 
obese postmenopausal women. LP and RES concentra-
tions were significantly and positively correlated with 
BMI, whereas ADIPO levels correlated negatively with 
both BMI and WHR. Nevertheless, several researchers 
did not find any relationship between RES levels and 
obesity markers (BMI, WHR, body fat mass) in obese 
female teenagers or moderately obese women [42, 84]. 
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The findings of VISF determinations have been also 
questionable. Similar to our results, Berndt et al. [48] also 
did not observe significant differences between serum 
VISF concentrations in obese and lean individuals. In 
addition, they did not find differences in VISF mRNA 
expression between visceral and subcutaneous adipose 
tissue. Other researchers demonstrated a decrease [49] 
or increase [50–52] of VISF concentrations in obese 
subjects. According to some authors [43, 85–90], the as-
sociation between LP, ADIPO, RES and VISF and obesity 
is lent support by changes in adipocytokine concentra-
tions following weight reduction (diet or surgery) in 
individuals with moderate or severe obesity. Significant 
weight reduction in women with moderate or severe 
obesity, apparently resulting from dietary treatment, 
has been found to be associated with decreased LP and 
RES and increased ADIPO circulating concentrations 
[85–87]. Weight loss after bariatric surgery in women 
and/or men with morbid obesity was associated with 
decreased LP, RES, VISF and increased ADIPO levels 
[43, 88–90]. Boucher et al. [47] postulated a relationship 
between obesity and APE upregulation. But it seems 
that obesity itself is not solely responsible for APE in-
crease; circulating levels of this adipocytokine are not 
significantly correlated with BMI [10, 91]. We did not 
reveal significant differences between serum APE in 
obese and non-obese postmenopausal women. Nei-
ther did we find a relationship between APE and BMI, 
although APE concentrations correlated significantly 
and positively with WHR. 
Our obese postmenopausal participants had a posi-
tive correlation between LP and BMD as well as the 
OPG/sRANKL ratio while the relationship between LP 
and OC, CTx, OPG and sRANKL levels was negative. 
Moreover, LP turned out to be an independent pre-
dictor of CTx, OPG, sRANKL and the OPG/sRANKL 
ratio in these women. Contrary to our present results, 
the correlation between LP and OPG, which we had 
previously observed in obese postmenopausal women 
[44,45], did not reach the level of statistical significance. 
Gannage-Yared et al. [55], did not find any correlation 
between LP and OPG levels, when they compared 
obese and non-obese young individuals. Women di-
agnosed with postmenopausal osteoporosis showed 
a weak correlation between LP and BMD and bone 
markers compared to the control group [78, 79], whereas 
obese postmenopausal women exhibited a stronger 
correlation between LP and BMD, bone markers (PICP, 
B-ALP or OC, CTx or NTx) than their non-obese post-
menopausal counterparts [44, 45, 69, 70]. This was most 
probably associated with decreased capacity of LP trans-
port in obese individuals providing a mechanism for 
LP resistance in the central nervous system (CNS) [92]. 
The levels of LP in the serum and cerebrospinal fluid 
(CSF) are well-correlated in normal weight individuals, 
whereas obese people exhibit high LP concentrations in 
the serum as opposed to only slight LP increases in the 
CSF [92]. It appears that LP mainly triggers bone tissue 
resorption and not formation in vivo [71]. It is gener-
ally believed that, only early in life, LP might stimulate 
bone growth and size through direct angiogenic and 
chondro-osteogenic effects. Later, in the mature skel-
eton, the hormone may decrease bone metabolism by 
stimulating the OPG/RANKL pathway. LP may also 
exert negative effects on bone tissue through a hypotha-
lamic pathway mediated by the sympathetic nervous 
system. These peripheral and central pathways of LP 
action could counterbalance each other. The peripheral 
and positive effects predominate when LP central re-
sistance occurs with obesity onset [14]. These findings 
are consistent with our previous [44, 45] and present 
results obtained for healthy obese postmenopausal 
women (with no insulin resistance, normal lipid profile 
and normal glucose tolerance test). 
Our findings seem to suggest that LP increase ob-
served in obese postmenopausal women might have 
a beneficial effect on bone metabolism. 
Considerably less data is available regarding the 
effects of obesity and menopause on the relationship 
between bone status indicators and ADIPO levels in 
women. The majority of research reports have focused 
on ADIPO concentrations and the association of this adi-
pocytokine with body mass determinants, bone markers, 
OPG and/or BMD in obese, and, particularly, moderately 
obese women. Some authors [55] did not find any cor-
relation between ADIPO and OPG levels when they 
compared obese and lean young individuals. In general, 
the obtained results indicate that obese women exhibited 
a BMI- and body fat percentage-dependent decrease in 
circulating ADIPO levels [9, 40–42]. A significant nega-
tive correlation between ADIPO concentrations and 
OPG has also been emphasised [40,82]. Postmenopausal 
women with MetS exhibited a high positive correlation 
between ADIPO levels and serum bone formation mark-
er — OC [56]. Wu et al. [57] reported that trunk fat mass 
increase in older women with MetS was significantly 
associated with lower ADIPO concentrations while leg 
fat mass was significantly associated with higher ADIPO 
levels [57]. Our findings seem to suggest that ADIPO 
deficiency observed in obese postmenopausal women 
(with no insulin resistance, normal lipid profile and 
normal glucose tolerance test) might have a beneficial 
effect on bone metabolism. A negative relation between 
serum ADIPO levels and BMD as well as a positive rela-
tionship with serum bone markers, OPG and sRANKL 
were confirmed among obese postmenopausal women. 
Moreover, ADIPO turned out to be an independent 
predictor of OC, OPG and sRANKL in these patients. 
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Though in vitro studies indicate significant relation-
ships between bone tissue metabolism and RES, VISF 
or APE levels [18–21], literature reports do not provide 
evidence confirming the occurrence of such relation-
ships in lean and obese persons. The few available in 
vivo investigations suggest the absence of a relationship 
between serum levels of the above mentioned adipo-
cytokines and BMD in non-obese women and men of 
different age [29, 31, 36, 37]. However, our results in 
obese postmenopausal women seem to indicate not 
only a significant association between BMD and serum 
APE (positive), but also a significant correlation between 
serum levels of OC and RES, VISF, APE (positive); serum 
levels of CTx and VISF, RES (negative); serum levels of 
sRANKL and RES (positive), APE (negative); the OPG/ 
/sRANKL ratio and serum VISF (negative). No signifi-
cant correlations were found between serum OPG and 
RES, VISF or APE levels. 
Hence, we conclude that changes in the concentra-
tions of the above mentioned adipose tissue hormones (a 
trend towards VISF and APE increase, plus a significant 
increase in RES concentrations) might have an effect (most 
probably beneficial) on bone metabolism and bone mass. 
Disparities in correlation analysis regarding adi-
pose tissue hormones and bone status determinants 
between women non-obese, obese (with no insulin 
resistance, normal lipid profile and normal glucose 
tolerance test), and suffering from MetS, might be as-
sociated with age differences, time from menopause 
and obesity-related complications [45, 59]. It should 
also be noted that osteoblasts and bone marrow stromal 
cells are not the only producers of OPG and RANKL 
[22, 23] as well as adipose tissue hormones (LP, ADIPO, 
RES, VISF, APE) are not only secreted by adipocytes 
[1, 2, 4]. Hence, the differences in the levels of these 
substances in the blood. The differences in the results 
of in vitro and in vivo studies might arise from the fact 
that the ultimate effect of adipose tissue hormones on 
in vivo bone status determinants might be modified by 
several well-known factors including hormones and 
cytokines [22, 23, 45, 65, 66].
Based on the above cited results, and our own find-
ings, it is possible that obesity itself as well as obesity-
related alterations in adipose tissue hormones might 
modify bone resorption in postmenopausal women 
not only directly but also via changes in the RANKL/ 
/RANKL/OPG system. Hence, it might be assumed that 
these alterations are included in a complex mechanism 
that acts to protect obese women against the develop-
ment of postmenopausal osteoporosis. 
The results of the present investigations indicate 
that the net effect of the investigated adipose tissue 
hormones on OPG and sRANKL concentrations in 
obese postmenopausal women most probably consists 
of a shift in the OPG/sRANKL ratio towards a functional 
excess of OPG. This is evidenced by the inhibition of 
the resorption process as reflected by a decrease in 
CTx, which functions as a resorption marker. Despite 
the disparities between the results of in vitro and in 
vivo studies, it might be assumed that adipose tissue 
hormones might exert a positive effect on the OPG/
sRANKL ratio via reducing the pool of active osteoclasts, 
thus diminishing the bone resorption process. This 
effect seems independent of whether adipose tissue 
hormones increase OPG expression, inhibit RANKL 
production or affect the expression of both cytokines. 
Conclusions
Obesity in postmenopausal women can lead to 
changes in BMD, circulating levels of bone mark-
ers, OPG, sRANKL and/or the OPG/sRANKL ratio; 
these changes are associated with alterations in the 
concentrations of adipose tissue hormones under 
investigation. 
The relationships between bone status indicators 
and adipose tissue hormones, especially LP and ADI-
PO, seem to suggest that postmenopausal changes in 
these hormones observed in obese women might have 
a protective effect on bone tissue, most probably via 
a shift in the OPG/sRANKL ratio towards a functional 
excess of OPG.
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